Illumina Stock Surges on Genomics Breakthroughs – What’s Next for ILMN?
Q3 2025 Earnings: Beat Expectations and Lifted Guidance Illumina’s latest quarterly report (Q3 FY2025) provided a much-needed spark for investors. The San Diego-based genomics giant reported $1.084 billion in revenue for Q3, slightly
